High-Specific-Activity- 131 I-MIBG versus 177 Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Abhishek Jha; David Taïeb; Jorge A Carrasquillo; Daniel A Pryma; Mayank Patel; Corina Millo; Wouter W de Herder; Jaydira Del Rivero; Joakim Crona; Barry L Shulkin; Irene Virgolini; Alice P Chen; Bhagwant R Mittal; Sandip Basu; Joseph S Dillon; Thomas A Hope; Carina Mari Aparici; Andrei H Iagaru; Rodney J Hicks; Anca M Avram; Jonathan R Strosberg; Ali Cahid Civelek; Frank I Lin; Neeta Pandit-Taskar; Karel Pacak

doi:10.1158/1078-0432.CCR-20-3703

Back

High-Specific-Activity- 131 I-MIBG versus 177 Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Journal article

Open access

Peer reviewed

High-Specific-Activity- 131 I-MIBG versus 177 Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Abhishek Jha, David Taïeb, Jorge A Carrasquillo, Daniel A Pryma, Mayank Patel, Corina Millo, Wouter W de Herder, Jaydira Del Rivero, Joakim Crona, Barry L Shulkin, …

Clinical cancer research, Vol.27(11), pp.2989-2995

06/01/2021

DOI: 10.1158/1078-0432.CCR-20-3703

PMCID: PMC8172462

PMID: 33685867

Files and links (1)

url

https://doi.org/10.1158/1078-0432.CCR-20-3703View

Published (Version of record) Open Access

Abstract

Targeted radionuclide therapies (TRT) using I-metaiodobenzylguanidine ( I-MIBG) and peptide receptor radionuclide therapy ( Lu or Y) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity- I-MIBG therapy was approved by the FDA and both Lu-DOTATATE and I-MIBG therapy were recommended by the National Comprehensive Cancer Network guidelines for the treatment of metastatic pheochromocytoma/paraganglioma. However, a clinical dilemma often arises in the selection of TRT, especially when a patient can be treated with either type of therapy based on eligibility by MIBG and somatostatin receptor imaging. To address this problem, we assembled a group of international experts, including oncologists, endocrinologists, and nuclear medicine physicians, with substantial experience in treating neuroendocrine tumors with TRTs to develop consensus and provide expert recommendations and perspectives on how to select between these two therapeutic options for metastatic/inoperable pheochromocytoma/paraganglioma. This article aims to summarize the survival outcomes of the available TRTs; discuss personalized treatment strategies based on functional imaging scans; address practical issues, including regulatory approvals; and compare toxicities and risk factors across treatments. Furthermore, it discusses the emerging TRTs.

Details

Title: Subtitle: High-Specific-Activity- 131 I-MIBG versus 177 Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
Creators: Abhishek Jha - Eunice Kennedy Shriver National Institute of Child Health and Human Development
David Taïeb - Aix-Marseille Université
Jorge A Carrasquillo - Memorial Sloan Kettering Cancer Center
Daniel A Pryma - University of Pennsylvania
Mayank Patel - Eunice Kennedy Shriver National Institute of Child Health and Human Development
Corina Millo - National Institutes of Health
Wouter W de Herder - Erasmus MC Cancer Institute
Jaydira Del Rivero - Center for Cancer Research
Joakim Crona - Uppsala University
Barry L Shulkin - St. Jude Children's Research Hospital
Irene Virgolini - Innsbruck Medical University
Alice P Chen - Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
Bhagwant R Mittal - Post Graduate Institute of Medical Education and Research
Sandip Basu - Homi Bhabha National Institute
Joseph S Dillon - University of Iowa Hospitals and Clinics
Thomas A Hope - University of California, San Francisco
Carina Mari Aparici - Stanford University School of Medicine
Andrei H Iagaru - Stanford University
Rodney J Hicks - The University of Melbourne
Anca M Avram - University of Michigan
Jonathan R Strosberg - Moffitt Cancer Center
Ali Cahid Civelek - Johns Hopkins University
Frank I Lin - National Institutes of Health
Neeta Pandit-Taskar - Memorial Sloan Kettering Cancer Center
Karel Pacak - Eunice Kennedy Shriver National Institute of Child Health and Human Development
Resource Type: Journal article
Publication Details: Clinical cancer research, Vol.27(11), pp.2989-2995
DOI: 10.1158/1078-0432.CCR-20-3703
PMID: 33685867
PMCID: PMC8172462
NLM abbreviation: Clin Cancer Res
ISSN: 1078-0432
eISSN: 1557-3265
Grant note: P30 CA008748 / NCI NIH HHS Z01 HD008735 / Intramural NIH HHS P30 CA086862 / NCI NIH HHS
Language: English
Date published: 06/01/2021
Academic Unit: Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism; Internal Medicine
Record Identifier: 9984359866402771

Metrics

14 Record Views

75 Times Cited - Web of Science

See more details